BioCentury

7:00 AM GMT, Apr 9, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

In the end, it's the royalty

Despite the positive Phase IIb asthma data reported by Theravance Inc. and partner GlaxoSmithKline plc for two of their long-acting adrenergic receptor beta 2 agonists, investors initially pushed THRX's share price down 3% on the news. A close look at the terms of the companies' 2002 deal to pool four LABAs from each company hints at the reason -

Read the full 594 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.